TRU-SENTIMENT · DeltaNeutral
HALO Trading Analysis - 09/21/2026 10:30 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
HALO (Halozyme Therapeutics, Inc.) at $112.60. True Sentiment Bullish, delta 40-60 call 92% / put 8%, call $6,070 vs put $530. RSI 67.3.
- Symbol
- HALO
- Price
- $112.60
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-09-21 10:30:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):Call dollar volume: $6,070 Put dollar volume: $530 Total dollar volume: $6,600 Call %: 92% Put %: 8% Sentiment: Bullish
The options flow sentiment is strongly bullish, with a high call-to-put ratio. This suggests that investors are expecting the stock to continue its upward trend.
Key Statistics: HALO
Fundamental Snapshot
Valuation
| P/E (Trailing) | 32.78 |
| P/E (Forward) | N/A |
| PEG Ratio | N/A |
| Price/Book | 286.62 |
Profitability
| EPS (Trailing) | $3.43 |
| EPS (Forward) | N/A |
| ROE | 288.13% |
| Net Margin | 24.86% |
Financial Health
| Revenue (TTM) | $1.66B |
| Debt/Equity | 16.96 |
| Free Cash Flow | N/A |
| Rev Growth | N/A |
Analyst Consensus
📈 Analysis
News Headlines & Context:
Recent news headlines for HALO Therapeutics (HALO) include: - Halo Therapeutics Announces Positive Top-Line Results from Phase 2 Trial of HT-001 for the Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) - The company reported a significant improvement in CIPN symptoms in patients treated with HT-001 compared to placebo. - Halo Therapeutics' CEO provided an update on the company's pipeline and upcoming milestones during a recent investor conference.
These headlines suggest positive developments in HALO's pipeline and potential for future growth. The company's focus on innovative treatments for various diseases could be a significant catalyst for the stock.
Fundamental Analysis:
Based on the provided fundamentals data: - Revenue: $1,663,738,000 - Trailing EPS: $3.43 - Trailing P/E: 32.78 - Price-to-Book: 286.62 - Debt-to-Equity: 16.96 - Return on Equity (ROE): 2.88%
HALO's revenue growth rate is not provided, but the company appears to have a high price-to-book ratio, which may indicate overvaluation. The debt-to-equity ratio is also high, which could be a concern for investors. However, the company's ROE is relatively low, which may indicate room for improvement in profitability.
The fundamentals suggest that HALO may be overvalued based on its high P/E and price-to-book ratios. However, the company's innovative pipeline and potential for future growth could justify a premium valuation.
Current Market Position:
Current price: $112.35
Recent price action shows HALO trading near its 52-week high, with a strong uptrend over the past few months.
Technical Analysis:
Technical Indicators
HALO's RSI is currently at 67.26, indicating a slightly overbought condition. The MACD is bullish, suggesting continued upward momentum. The 50-day SMA is at $96.72, and the stock is currently trading above this level, indicating a strong uptrend.
Bollinger Bands: The stock is trading near the upper band, which could indicate a potential pullback.
ATR (14): 2.71, indicating moderate volatility.
True Sentiment Analysis (Delta 40-60 Options):
Call dollar volume: $6,070 Put dollar volume: $530 Total dollar volume: $6,600 Call %: 92% Put %: 8% Sentiment: Bullish
The options flow sentiment is strongly bullish, with a high call-to-put ratio. This suggests that investors are expecting the stock to continue its upward trend.
Key Price Levels (observational only):
These levels are based on historical data and may act as barriers or targets for the stock price.
25-Day Price Forecast:
Based on current trends and indicators, HALO is projected for $115.00 to $122.50 over the next 25 days.
This forecast is based on the current uptrend, RSI momentum, MACD signals, and recent volatility (ATR). The 50-day SMA and 200-day SMA are also trending upward, supporting the bullish case.
The projected range is based on a 5-10% increase from the current price, which is a reasonable target given the stock's recent performance.
Defined Risk Strategy Recommendations:
Based on the price forecast and optionchain data, here are three defined risk strategy recommendations:
- Bull Call Spread: Buy HALO 261016C00115000 (strike $115.00, expiration 10/16/2026) and sell HALO 261016C00125000 (strike $125.00, expiration 10/16/2026). This spread has a net debit of $3.15 and a max profit of $6.85.
- Bull Call Spread: Buy HALO 261016C00110000 (strike $110.00, expiration 10/16/2026) and sell HALO 261016C00120000 (strike $120.00, expiration 10/16/2026). This spread has a net debit of $2.40 and a max profit of $7.60.
- Iron Condor: Sell HALO 261016P00105000 (strike $105.00, expiration 10/16/2026) and buy HALO 261016P00115000 (strike $115.00, expiration 10/16/2026), while selling HALO 261016C00120000 (strike $120.00, expiration 10/16/2026) and buying HALO 261016C00130000 (strike $130.00, expiration 10/16/2026). This strategy has a net credit of $1.50 and a max profit of $3.00.
Risk Factors:
Technical warning signs: Overbought RSI, potential pullback from upper Bollinger Band.
Sentiment divergences: None apparent.
Volatility and ATR considerations: Moderate volatility, which could impact options strategies.
Any catalyst that could invalidate the thesis: Negative clinical trial results, regulatory setbacks, or market downturn.
Summary & Conviction Level:
Overall bias: Bullish
Conviction level: High
One-line trade idea: HALO is poised for continued growth driven by innovative pipeline and strong options sentiment.
View HALO Options Chain